4
Changes in Ownership
Cullinan Therapeutics, Inc. Filed Acc 0000950170-23-027063
Chief Development Officer sold 12,000 shares at an average $12.31 ($147,729)
- Chief Development Officer acquired 12,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Michaelson Jennifer Chief Development Officer | 2023-06-06 | Option exercise 10b5-1 | +11,900 | $4.30 | $51,170 | 102,347 | D |
| Michaelson Jennifer Chief Development Officer | 2023-06-06 | Sale 10b5-1 | −11,900 | $12.31 | $146,489 | 90,447 | D |
| Michaelson Jennifer Chief Development Officer | 2023-06-07 | Option exercise 10b5-1 | +100 | $4.30 | $430 | 90,547 | D |
| Michaelson Jennifer Chief Development Officer | 2023-06-07 | Sale 10b5-1 | −100 | $12.40 | $1,240 | 90,447 | D |
| Derivatives | |||||||
| Michaelson Jennifer Chief Development Officer | 2023-06-06 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −11,900 | 188,693 | D | ||
| Michaelson Jennifer Chief Development Officer | 2023-06-07 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100 | 188,593 | D | ||
| Open-market sales · 12,000 sh · avg $12.31 · $147,729 | |||||||
Loading xslF345X04/ownership.xml…